Omnicell (NASDAQ:OMCL) EVP Sells $129,010.00 in Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 3,880 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the completion of the transaction, the executive vice president directly owned 110,653 shares in the company, valued at $3,679,212.25. The trade was a 3.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Omnicell Stock Up 2.0%

Shares of OMCL stock opened at $31.80 on Friday. The stock’s 50 day simple moving average is $30.90 and its 200 day simple moving average is $30.93. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.74. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of 63.60, a PEG ratio of 6.81 and a beta of 0.82.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Bank of America boosted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, May 23rd. Wall Street Zen downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Wells Fargo & Company upped their price objective on Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, July 21st. Finally, Piper Sandler dropped their price objective on Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Institutional Trading of Omnicell

Several institutional investors and hedge funds have recently bought and sold shares of OMCL. Raymond James Financial Inc. bought a new position in shares of Omnicell during the second quarter worth approximately $26,000. GAMMA Investing LLC increased its stake in shares of Omnicell by 37.1% during the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock worth $50,000 after purchasing an additional 458 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Omnicell by 385.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company’s stock worth $146,000 after purchasing an additional 3,932 shares during the period. AlphaQuest LLC increased its stake in shares of Omnicell by 79.0% during the first quarter. AlphaQuest LLC now owns 6,400 shares of the company’s stock worth $224,000 after purchasing an additional 2,824 shares during the period. Finally, New Age Alpha Advisors LLC bought a new position in shares of Omnicell during the first quarter worth approximately $233,000. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.